Balanced news tone
News Sentiment
DNTH sentiment intelligence
Dianthus Therapeutics Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
54
Balanced news tone
54 relevant articles
News tone and price action are not far from neutral.
82/100 classification confidence.
directly relevant articles
high-authority source matches
+3.5% over one week, +18.9% over four weeks, trend active, and materially above fair value.
Form 4 Dianthus Therapeutics Inc For: 13 July By Investing.com
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
82/100 classification
One-week reaction
3.5%
Price confirming higher
Trend fit
Trend active
18.9% over four weeks
Fair value
194.3%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
14
Neutral
33
Negative
7
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Investing.com Nigeria
Direct company coverage
Form 4 Dianthus Therapeutics Inc For: 13 July By Investing.com
This article from Investing.com reports that Dianthus Therapeutics Inc. submitted a Form 4 on July 13. The company's stock symbol is DNTH, and it experienced a slight increase of 0.96% at the time of publication. The brief report serves as an announcement for the financial filing
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 22:14
- Source
- Investing.com Nigeria
Investing.com
Direct company coverage
Dianthus therapeutics CFO Ryan Savitz sells $3.16 million in shares
Dianthus Therapeutics CFO Ryan Savitz sold 31,249 shares of common stock for approximately $3.16 million on July 9, 2026, through a Rule 10b5-1 trading plan. This sale occurred after he exercised stock options to acquire the same number of shares, which were vested monthly over f
- Tone
- Negative 39/100
- Event
- Market update
- Published
- 13 Jul 2026 21:41
- Source
- Investing.com
Stock Titan
Direct company coverage
[Form 4] Dianthus Therapeutics, Inc. /DE/ Insider Trading Activity
Dianthus Therapeutics' EVP, CFO & CBO, Ryan Savitz, exercised stock options for 31,249 shares and subsequently sold them in open-market transactions for approximately $3.16 million, as detailed in a recent Form 4 filing. These sales were conducted under a Rule 10b5-1 trading plan
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 13 Jul 2026 20:41
- Source
- Stock Titan
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Sahm
Direct company coverage
Dianthus Therapeutics (DNTH) Starts Phase 3 EMERGE Trial, Is The Upside Already Priced In?
Dianthus Therapeutics (DNTH) has initiated its Phase 3 EMERGE trial for claseprubart in generalized Myasthenia Gravis, and the stock has experienced significant appreciation recently. Despite a high valuation compared to the broader biotech industry, it appears undervalued agains
- Tone
- Positive 63/100
- Event
- Market update
- Published
- 11 Jul 2026 02:40
- Source
- Sahm
Stock Titan
Direct company coverage
[144] Dianthus Therapeutics, Inc. /DE/ SEC Filing
This article details a Form 144 SEC filing by Dianthus Therapeutics, Inc. (DNTH) concerning a proposed sale of 31,249 common shares with an aggregate market value of $3,064,589.43. The shares were acquired on July 9, 2026, through the exercise of stock options and are intended to
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 20:03
- Source
- Stock Titan
TradingView
Direct company coverage
Price to earnings forward of Dianthus Therapeutics, Inc. – MUN:87E
The article provides a simple statement about the "Price to earnings forward" for Dianthus Therapeutics, Inc. (MUN:87E) on the Munich Stock Exchange. It indicates no trading activity and shows a placeholder for a period, value, and change, suggesting that specific financial data
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 08 Jul 2026 11:10
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH
This article provides an analysis of the enterprise value to revenue forward for Dianthus Therapeutics, Inc. (NASDAQ: DNTH). It appears to be a financial snapshot from TradingView, highlighting key financial metrics for the company. The content focuses on the valuation of the com
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 06 Jul 2026 04:11
- Source
- TradingView
Finviz
Direct company coverage
DNTH - Dianthus Therapeutics Inc Revenue Breakdown
This article provides a comprehensive financial overview of Dianthus Therapeutics Inc (DNTH), detailing its revenue breakdown, key financial metrics, stock performance, and insider/institutional ownership. It includes various ratios like P/S, P/B, and profitability margins, along
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 05 Jul 2026 13:44
- Source
- Finviz
Market source
Direct company coverage
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
Dianthus Therapeutics, Inc. announced that it granted equity awards to five newly-hired, non-executive employees on July 1, 2026. These inducement grants, approved by the independent Compensation Committee, consist of non-qualified stock options to purchase an aggregate of 58,000
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 03 Jul 2026 12:10
- Source
- Market source
Stock Titan
Direct company coverage
Dianthus gives 5 new hires stock options worth 58,000 shares
Dianthus Therapeutics granted 58,000 non-qualified stock options to five new non-executive employees on July 1, 2026, as an inducement under Nasdaq Listing Rule 5635(c)(4). These options have a 10-year term, an exercise price of $90.21 per share, and a four-year vesting schedule.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 02 Jul 2026 19:40
- Source
- Stock Titan
Sahm
Direct company coverage
Dianthus Therapeutics (DNTH) Starts Phase 3 Trial, Is The Stock Still A Bargain?
Dianthus Therapeutics (DNTH) is gaining attention after initiating its EMERGE global Phase 3 trial for claseprubart in generalized Myasthenia Gravis, following positive Phase 2 data and Orphan Drug Designation. Despite recent volatility and removal from Russell indices, the stock
- Tone
- Positive 63/100
- Event
- Market update
- Published
- 02 Jul 2026 13:44
- Source
- Sahm
TradingView
Direct company coverage
Price to book forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH
This article provides a financial metric, "Price to book forward," for Dianthus Therapeutics, Inc. (NASDAQ: DNTH). It is presented on the TradingView platform, which offers various financial tools and data for investors. The content is primarily a listing of navigation and footer
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 01 Jul 2026 22:39
- Source
- TradingView
Sahm
Direct company coverage
Why Dianthus Therapeutics (DNTH) Is Up 11.4% After Launching Its Phase 3 EMERGE gMG Trial
Dianthus Therapeutics saw its stock rise by 11.4% after initiating the global Phase 3 EMERGE trial for its investigational antibody claseprubart in generalized Myasthenia Gravis (gMG). This follows promising Phase 2 data and FDA Orphan Drug Designation. The trial aims to offer an
- Tone
- Positive 65/100
- Event
- Regulatory and legal
- Published
- 30 Jun 2026 12:40
- Source
- Sahm
Investing.com
Direct company coverage
Dianthus Therapeutics stock hits 52-week high at 96.85 USD
Dianthus Therapeutics (DNTH) stock has hit a new 52-week high of $96.85, achieving a market capitalization of $5.21 billion and demonstrating significant growth with a 1-year total return of over 440%. Despite an InvestingPro analysis suggesting it may be overvalued, the company'
- Tone
- Positive 71/100
- Event
- Market update
- Published
- 29 Jun 2026 14:40
- Source
- Investing.com
Investing.com Canada
Direct company coverage
Dianthus Therapeutics stock hits 52-week high at 96.85 USD By Investing.com
Dianthus Therapeutics stock has reached a 52-week high of $96.85, pushing its market capitalization to $5.21 billion, despite an InvestingPro analysis suggesting it might be overvalued. The company has seen significant growth with a 440.84% 1-year return and 131% year-to-date gai
- Tone
- Positive 85/100
- Event
- Market update
- Published
- 29 Jun 2026 13:39
- Source
- Investing.com Canada
MT Newswires
Direct company coverage
Dianthus Therapeutics Begins Phase 3 Trial of Treatment for Rare Autoimmune Disorder
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 12:05
- Source
- MT Newswires
The Manila Times
Direct company coverage
Dianthus Therapeutics Announces Initiation of Phase 3 Emerge Trial of Claseprubart in Generalized Myasthenia Gravis
Dianthus Therapeutics has initiated the Phase 3 EMERGE trial for claseprubart, a treatment for generalized Myasthenia Gravis (gMG). This global, randomized, placebo-controlled study will evaluate subcutaneous doses of claseprubart in approximately 195 participants, with top-line
- Tone
- Positive 73/100
- Event
- Market update
- Published
- 29 Jun 2026 10:39
- Source
- The Manila Times
Stock Titan
Direct company coverage
Dianthus launches Phase 3 study of claseprubart in rare muscle disease
Dianthus Therapeutics has initiated the global Phase 3 EMERGE trial for claseprubart in patients with generalized myasthenia gravis (gMG) who are AChR+. This placebo-controlled study will involve approximately 195 participants to evaluate subcutaneous dosing regimens (Q2W and Q4W
- Tone
- Positive 70/100
- Event
- Market update
- Published
- 29 Jun 2026 10:39
- Source
- Stock Titan
www.marketscreener.com
Direct company coverage
Dianthus Therapeutics, Inc.(NasdaqCM: DNTH) dropped from Russell 3000E Index
Dianthus Therapeutics, Inc. (NasdaqCM:DNTH) has been removed from the Russell 3000E Index. The company, a clinical-stage biotechnology firm, focuses on developing therapies for severe autoimmune diseases with lead candidates like claseprubart and DNTH212. Recent news includes pre
- Tone
- Negative 39/100
- Event
- Market update
- Published
- 29 Jun 2026 09:48
- Source
- www.marketscreener.com
www.marketscreener.com
Direct company coverage
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell Microcap Growth Benchmark Index
Dianthus Therapeutics, Inc. (NasdaqCM:DNTH) has been removed from the Russell Microcap Growth Benchmark Index. The company is a clinical-stage biotechnology firm developing therapies for severe autoimmune diseases, with its lead candidate, claseprubart, undergoing multiple clinic
- Tone
- Negative 30/100
- Event
- Market update
- Published
- 29 Jun 2026 08:40
- Source
- www.marketscreener.com
TradingView
Direct company coverage
Price to sales forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH
This article provides financial information for Dianthus Therapeutics, Inc. (NASDAQ: DNTH), specifically its price-to-sales forward metric. The content was sourced from TradingView and includes data from ICE Data Services and FactSet.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 22:39
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH
This article provides the "Price to earnings forward" value for Dianthus Therapeutics, Inc. (NASDAQ: DNTH). It appears to be an unpopulated data point from a financial platform like TradingView, indicating that the specific financial metric is not available for the company at the
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 28 Jun 2026 16:09
- Source
- TradingView
Finviz
Direct company coverage
DNTH - Dianthus Therapeutics Inc Options
This article provides a comprehensive financial snapshot of Dianthus Therapeutics Inc (DNTH), a biotechnology company. It details key financial metrics including market capitalization, revenue, earnings, insider and institutional ownership, profitability ratios, and stock perform
- Tone
- Positive 62/100
- Event
- Earnings
- Published
- 28 Jun 2026 12:10
- Source
- Finviz
TradingView
Direct company coverage
Price to book forward of Dianthus Therapeutics, Inc. – DUS:87E
This article provides the "Price to book forward" for Dianthus Therapeutics, Inc. (DUS:87E) on the Dusseldorf Stock Exchange. It indicates that the market is currently closed with no trades recorded. The content seems to be a financial data point from a trading platform.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jun 2026 06:42
- Source
- TradingView
TradingView
Direct company coverage
DNTH Forecast — Price Target — Prediction for 2027
The article provides a forecast for Dianthus Therapeutics, Inc. (DNTH) stock, including a 1-year price target of 127.85 USD based on 13 analysts. It details recent stock performance, analyst estimates for future prices ranging from 98.00 USD to 200.00 USD, and financial metrics s
- Tone
- Positive 72/100
- Event
- Analyst action
- Published
- 27 Jun 2026 09:42
- Source
- TradingView
TradingView
Direct company coverage
Dianthus Therapeutics, Inc. Actuals & Estimates (FWB:87E)
This article provides an overview of Dianthus Therapeutics, Inc. (FWB:87E) financial actuals and estimates, stock performance, and analyst forecasts. It covers the current stock price, historical highs and lows, market capitalization, earnings reports, and volatility. The company
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 26 Jun 2026 06:41
- Source
- TradingView
TradingView
Direct company coverage
A3ERZ4 Forecast — Price Target — Prediction for 2027
This article provides a forecast for Dianthus Therapeutics, Inc. (A3ERZ4) stock, including analyst price targets, historical performance, and key financial metrics. It details the company's valuation, earnings, revenue, and market capitalization, offering insights into its stock
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 13:39
- Source
- TradingView
Stock Titan
Direct company coverage
Dianthus (DNTH) SVP uses 10b5-1 plan to sell 30,000 shares
Dianthus Therapeutics' SVP and General Counsel, Adam M. Veness, reported an exercise-and-sale transaction involving 30,000 shares of company stock. He exercised stock options at $17.88 per share and subsequently sold the same number of shares in open-market transactions under a R
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 20:40
- Source
- Stock Titan
Simply Wall St.
Direct company coverage
Dianthus CIDP Data Lift Prospects While Funding And Dilution Risks Linger
- Tone
- Negative 42/100
- Event
- Market update
- Published
- 15 Jun 2026 11:09
- Source
- Simply Wall St.